Compare IBRX & CIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBRX | CIVI |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | N/A | 2011 |
| Metric | IBRX | CIVI |
|---|---|---|
| Price | $6.23 | $27.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | $11.80 | ★ $40.20 |
| AVG Volume (30 Days) | ★ 46.1M | 1.2M |
| Earning Date | 03-02-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 7.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.86 |
| Revenue | $82,555,000.00 | ★ $4,711,808,000.00 |
| Revenue This Year | $680.06 | N/A |
| Revenue Next Year | $90.18 | N/A |
| P/E Ratio | ★ N/A | $3.94 |
| Revenue Growth | ★ 1025.95 | N/A |
| 52 Week Low | $1.83 | $22.79 |
| 52 Week High | $8.28 | $53.02 |
| Indicator | IBRX | CIVI |
|---|---|---|
| Relative Strength Index (RSI) | 75.41 | 55.91 |
| Support Level | $5.71 | $25.83 |
| Resistance Level | $8.28 | $28.41 |
| Average True Range (ATR) | 0.67 | 1.12 |
| MACD | 0.42 | 0.21 |
| Stochastic Oscillator | 67.10 | 84.18 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.